Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wohlrab, Johannes
ETSKABI, NCT04814511: Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)	Recruiting	3	183	Europe	InfectoScab 5 % Creme, Permethrin 10 % Creme, Driponin 3 mg Tabletten	Infectopharm Arzneimittel GmbH, Winicker Norimed GmbH	Scabies	12/22	08/23
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata	Recruiting	3	595	Europe, Canada, Japan, US, RoW	Baricitinib, LY3009104, Placebo	Eli Lilly and Company	Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical	09/24	08/29
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus	Recruiting	2/3	474	Europe, Canada, Japan, US, RoW	Litifilimab, BIIB059, Placebo	Biogen, Biogen Idec Research Limited	Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus	10/26	12/27
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022 Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022 Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021 Jun 2021 - Jun 2021: Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021 Preliminary data from cohort 2 of TELLOMAK trial for mycosis fungoides Jun 2021 - Jun 2021: Preliminary data from cohort 2 of TELLOMAK trial for mycosis fungoides First patient in trial for PTCL Sep 2019 - Sep 2019: First patient in trial for PTCL Enrollment of first patient in TELLOMAK trials for Sezary syndrome May 2019 - May 2019: Enrollment of first patient in TELLOMAK trials for Sezary syndrome More	Active, not recruiting	2	170	Europe, US	IPH4102, lacutamab	Innate Pharma	Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome	10/23	01/26